*This analysis excludes the 284 participants who did not receive beta-blockers at baseline who had documented beta-blocker use during medication reconciliation at any follow-up visit (n=103) and those who received beta-blockers at baseline who had follow-up visits at which medication reconciliation documented no beta-blocker use (n=181). We censored at the time of first heart failure hospitalization for these comparisons. The interaction between an EF threshold of 50% and beta-blocker use and incident HF hospitalizations in the fully adjusted model achieved statistical significance (p=0.007). This analysis excludes participants who did not receive beta-blockers at baseline who had documented beta-blocker use during medication reconciliation at any follow-up visit and those who received beta-blockers at baseline who had follow-up visits at which medication reconciliation documented no beta-blocker use. We censored at the time of first heart failure hospitalization for these comparisons. The interaction between EF and beta-blocker use and incident HF hospitalizations was statistically significant (p=0.046).The hazard ratios for patients with an EF 45-49 could not be estimated due to the small number of matched sets. 
